After an interim analysis, NewLink Genetics is planning to keep on keeping on with a Phase III study of its cancer vaccine. But that news came as an apparent disappointment to investors, who hoped the drug's promise would result in an early trial termination, and the biotech's shares fell more than 12% on Friday morning.
Bethesda, MD's Northwest Biotherapeutics has watched as rivals Dendreon and ImmunoCellular have run into serious roadblocks with personalized cancer vaccines over the past year, but with a major Phase III study underway, the biotech believes it can change the narrative.
GlaxoSmithKline's MAGE-A3 cancer vaccine was viewed as a long shot by some analysts even before it missed its first co-primary endpoint last year. Yet while analysts lowered expectations in the wake of the weak data in melanoma patients, GSK is continuing to promote its prospects.
Germany's Medigene AG has nabbed a small cancer vaccine developer in a buyout which will add a team of investigators from one of the country's top research institutes. Medigene agreed to pay about 4 million euros in stock for Trianta Immunotherapies, with another 6 million euro chunk held aside for possible milestone payments.
ImmunoCellular Therapeutics put out the word Wednesday afternoon that its dendritic cell-based vaccine for brain cancer flunked the key overall survival test in Phase II, news that swiftly wiped out more than half of the small biotech's market cap as shares instantly cratered.
A few months after Jennerex and its partner Transgene reported that their oncolytic cancer vaccine Pexa-Vec flunked a Phase IIb endpoint on overall survival in liver cancer, the private South Korean CRO SillaJen has stepped in to buy the company in a deal worth up to $150 million at the high end.
A pair of prominent pharma players are partnering up with a few marquee European VCs to back an up-and-coming immunotherapy biotech based in Vienna.
Cancer vaccine developer Galena Biopharma has filed a libel suit against the co-inventor of its lead candidate.
Agenus has struck a deal to raise about $6.5 million from institutional backers in a direct offering of common stock and warrants. The financing was announced a day after the Lexington, MA-based biotech company revealed that patients with glioblastoma multiforme, a cancer which attacks the brain, who took its experimental vaccine lived more than twice as long without their cancer getting worse than those on the standard of care.
Coming into 2013 GlaxoSmithKline highlighted a cancer vaccine as one of its brightest late-phase candidates. Yet, like many cancer vaccines before it, MAGE-A3 has disappointed at the final hurdle.